Epidermal growth factor receptor mutation analysis in advanced non-small cell lung cancer: review of economic evaluations and framework for economic analyses
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001150
English
Authors' recommendations:
This report systematically reviewed the existing evidence on the cost-effectiveness of the EGFR mutation analysis. Our review found one preliminary cost-effectiveness study (a conference presentation), showing that the EGFR mutation analysis is cost-effective compared with no-testing strategy, if the society’s threshold for cost per additional progression-free survival year was US$17,184. However, the modeling structure was restrictive because (1) progression-free survival (not the overall survival) was the primary outcome, (2) impacts of therapies on HRQL were not considered, and (3) most importantly, treatment sequence was not modelled. Given the relatively early phase of the technological development of the EGFR mutation analysis, an economic framework was developed to provide guidance for analysts in conducting future cost-effectiveness analyses on the EGFR mutation analysis. Our economic modeling framework described comprehensive decision-analytic models to assess cost-effectiveness of EGFR mutation analysis to select first-line therapies for advanced NSCLC patients. The proposed framework reflects closely the CADTH economic guideline and the recently published CADTH oncology guidelines. With the accumulation of clinical evidence on the test validity and clinical utility of EGFR mutation analysis, analysts will be able to conduct formal cost-effectiveness analyses, which help guide future reimbursement decisions on EGFR mutation analysis.
Details
Project Status:
Completed
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Cost-Benefit Analysis
- Lung Neoplasms
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.